<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946046</url>
  </required_header>
  <id_info>
    <org_study_id>2017_68</org_study_id>
    <secondary_id>2018-A02045-50</secondary_id>
    <nct_id>NCT03946046</nct_id>
  </id_info>
  <brief_title>Targeting Methods of Botulinum Toxin Injections for Cervical Dystonia</brief_title>
  <acronym>RINOCERAUS</acronym>
  <official_title>Results of Botulinum Toxin Injections for Cervical Dystonia : Benefits of Ultrasonography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin injections are the treatment of choice for cervical dystonia. Even if this&#xD;
      treatment is successful for most of the patients, partials or completes failures still&#xD;
      remained.&#xD;
&#xD;
      Usually, botulinum toxin injections are realized by clinical localization techniques&#xD;
      (observation and palpation of target muscles). The use of Ultrasonography to guide injections&#xD;
      of Botulinum toxin has theoretical benefits (as an improved precision, an improved&#xD;
      reproducibility, the targeting of deep-seated muscles, and a lower risk of adverse events)&#xD;
      but its interest has never been demonstrated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label non-randomised controlled clinical trial comparing clinical localization&#xD;
      techniques and ultrasonography to guide injections of Botulinum toxin A.&#xD;
&#xD;
      The primary outcome is to compare both techniques of injection regarding to the health impact&#xD;
      of cervical dystonia (CDIP-58) measured 1 month after injection.&#xD;
&#xD;
      The results of this clinical trial will help the clinician to decide which strategy of&#xD;
      injection is the most effective in terms of benefit/risk ratio to treat the cervical&#xD;
      dystonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical Dystonia Impact Profile 58 (CDIP-58)</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Variation of the total score obtained with The Cervical Dystonia Impact Profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placement of the injecting needle</measure>
    <time_frame>the day of the inclusion</time_frame>
    <description>Assessment of the accurate placement of the injecting needle within the target muscle by ultrasonography in patients injected by the clinical targeting method (number and percent of discordances)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCI-I (Clinical Global Impressions - Improvement) patient scale</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Variation of the GCI-I (Clinical Global Impressions - Improvement) patient scale :&#xD;
= Very much improved : nearly all better; good level of functioning; minimal symptoms; represents a very substantial change&#xD;
= Much improved : notably better with significant reduction of symptoms; increase in the level of functioning but some symptoms remain&#xD;
= Minimally improved : slightly better with little or no clinically meaningful reduction of symptoms. Represents very little change in basic clinical status, level of care, or functional capacity&#xD;
= No change : symptoms remain essentially unchanged&#xD;
= Minimally worse : slightly worse but may not be clinically meaningful; may represent very little change in basic clinical status or functional capacity&#xD;
= Much worse : clinically significant increase in symptoms and diminished functioning&#xD;
= Very much worse : severe exacerbation of symptoms and loss of functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TWSTRS-2 (Toronto Western Spasmodic Torticollis Rating Scale) : pain scale only</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Variation of the TWSTRS-2 (Toronto Western Spasmodic Torticollis Rating Scale) : pain scale only&#xD;
Total score = 0 (no pain) to 40 (maximal pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TWSTRS-PSYCH (Toronto Western Spasmodic Torticollis Rating Scale - Psychiatric) scale</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Variation of the TWSTRS-PSYCH (Toronto Western Spasmodic Torticollis Rating Scale - Psychiatric) scale&#xD;
Total score = 0 (no psychiatric disorders) to 24 (important psychiatric disorders)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>1 month after inclusion</time_frame>
    <description>Adverse events related to the botulinum toxin injection (pain, swallowing disorders, hematoma, muscular weakness, dry mouth)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Idiopathic Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Clinical targeting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical localization method (observation and palpation of target muscles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasonography targeting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrason-guided method</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical targeting</intervention_name>
    <description>The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)</description>
    <arm_group_label>Clinical targeting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonography targeting</intervention_name>
    <description>The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method</description>
    <arm_group_label>Ultrasonography targeting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient older than 18 years old&#xD;
&#xD;
          -  Focal idiopathic cervical dystonia treated by injections of Botulinum toxin type A&#xD;
             (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ; or incobotulinumtoxinA,&#xD;
             Xeomin®).&#xD;
&#xD;
          -  Patient who have previously received at least 3 cycles of botulinum toxin A injections&#xD;
             in this specific indication&#xD;
&#xD;
          -  Injections realized with clinical targeting exclusively or ultrasonography targeting&#xD;
             exclusively&#xD;
&#xD;
          -  Patient who is not opposed to its participation in this study&#xD;
&#xD;
          -  Patient affiliated to the Sécurité Sociale&#xD;
&#xD;
          -  Patient able to comply with study procedures and study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman pregnant, woman of childbearing age not taking effective contraception or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Contraindication of botulinum toxin injections as :&#xD;
&#xD;
               -  Hypersensivity to the botulinum toxin A or to an excipient of the commercialized&#xD;
                  treatment (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ;&#xD;
                  incobotulinumtoxinA, Xeomin®)&#xD;
&#xD;
               -  Generalized muscular activity disorder (Myasthenia gravis, Lambert-Eaton&#xD;
                  syndrome)&#xD;
&#xD;
               -  Infection or inflammation of the injection site&#xD;
&#xD;
          -  Concomitant treatment that can interact with botulinum toxin A or modify the function&#xD;
             of the neuromuscular synapse junction (anticholinergics, curare and other myorelaxing&#xD;
             agents, Aminoglycosides, amino-4-quinolines)&#xD;
&#xD;
          -  Documented resistance to the botulinum toxin A&#xD;
&#xD;
          -  Inability to receive the information, inability to participate to the all study&#xD;
             duration, refusal to sign the consent&#xD;
&#xD;
          -  EMG-guided botulinum toxin injections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre KREISLER, MD, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Roger Salengro, CHRU Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille - Service de neurologie A</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical dystonia</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>Ultrasound-guided injection</keyword>
  <keyword>CDIP58</keyword>
  <keyword>TWSTRS-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

